

Date: August 13, 2025

To,
BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544449

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Subject: Earnings Call Presentation of the Company Pertaining to Q1 of FY 2025-26

Dear Sir/Ma'am

In continuation with the Company's letter dated August 08, 2025, pertaining to intimation of schedule of earnings call to be held on Thursday, August 14, 2025, at 12:00 PM (IST)/14:30 SGT/HKT and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the earnings presentation on the Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2025.

The same is also available on the Company's website at <https://www.anthembio.com/investor.html>.

We request you to kindly take the same on record.

Thanking you,

Yours truly,
For Anthem Biosciences Limited
(Formerly known as Anthem Biosciences Private Limited)

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438



Anthem Biosciences Limited

Investor Presentation

August 13, 2025

Safe Harbour







Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.



Consolidated Profit & Loss Statement

Particulars (₹ Mn)	Q1FY26	Q1FY25	YoY	Q4FY25	QoQ	FY25
Revenue from Operations	5,402	3,386	59.5%	4,832	11.8%	18,446
<i>CRDMO</i>	4,527	2,655	70.5%	3,923	15.4%	15,061
<i>Specialty Ingredients</i>	875	731	19.7%	909	-3.8%	3,385
Other Income	228	195	17.3%	141	62.2%	857
Total Revenues	5,630	3,580	57.3%	4,973	13.2%	19,303
Cost of materials consumed and changes in inventories	2,309	1,465	57.6%	1,768	30.6%	7,439
Employee benefits expense	720	475	51.8%	598	20.5%	2,605
Other expenses	458	237	93.2%	514	-10.8%	1,693
EBITDA	2,143	1,404	52.7%	2,092	2.4%	7,566
EBITDA Margins	38.1%	39.2%	-1.1%	42.1%	-4.0%	39.2%
Finance cost	16	37	-56.5%	5	209.0%	103
Depreciation and amortization expense	264	187	41.6%	304	-13.1%	894
Profit before tax	1,862	1,180	57.9%	1,783	4.5%	6,569
Total tax expense	505	356	41.8%	957	-47.3%	2,056
Profit after tax	1,358	824	64.8%	826	64.4%	4,513

Q1FY26 Consolidated Financial Highlights



Strong financial performance with robust return profile for Q1FY26

 Strong Business Performance	₹5,402 Mn Q1FY26 Revenues	38.1% Q1FY26 EBITDA Margin	24.1% Q1FY26 PAT Margin
 Robust Technology and Infrastructure¹	2,149 / 1,045 # Employees / Scientific Staff	324KL¹ Custom Synthesis Capacity	142KL Fermentation Capacity
 Strong Returns and Balance Sheet	21.8% / 28.2% ROE / Q1FY26 Post Tax ROCE	1.64x Q1FY26 Gross Fixed Assets Turnover	1.01x Net Cash / Q1FY26 EBITDA

¹ Note: 54KL out of the 130 KL expansion at Unit II commissioned in Q1FY26

Q1FY26 Financial Highlights

- Consolidated Revenue from Operations was ₹5,402 Mn for the quarter
 - CRDMO business delivered ₹4,527 Mn revenues
 - Specialty Ingredients delivered ₹875 Mn revenues
- EBITDA was ₹2,143 Mn, with EBITDA margins at 38%
- PAT (Profit After Tax) was ₹1,358 Mn, with PAT margins at 24%
- Net Cash position as of June 30, 2025, is ₹7,848 Mn

Q1FY26 Business Highlights

Capex and Investment Highlights

- Unit II (Harohalli):
 - Completed the expansion of 54 kL custom synthesis capacity at Unit II and commenced commercial operations
- Unit III (NeoAnthem, Harohalli):
 - Completed and commenced operations at Unit III in a phased manner - commenced operations at the custom synthesis block comprising R&D laboratory, pilot laboratory, kilo laboratory, hydrogenation facility
 - Inaugurated new, state-of-the-art, dedicated commercial scale peptide manufacturing facility (16kL capacity) and commercial scale hi-potent manufacturing facility (2.5kL capacity)
- Unit IV (Harohalli):
 - Broke ground and construction underway for a new greenfield facility at the 30 acre site at Harohalli, Bangalore

Message from Chairman, MD and CEO



AJAY BHARDWAJ
Chairman, MD & CEO

“We have kicked off FY26 with a strong performance, laying a solid foundation for the year ahead. Strong YoY (Year on Year) growth in Q1FY26 reflects a CRDMO revenue stream that started ramping up since Q2FY25. A combination of a dedicated team, strategic focus, operational excellence and long-standing client partnerships has helped us deliver performance across both CRDMO and Specialty Ingredients business”.



Thank You

Anthem Biosciences Limited

Unit I: No.49, F1 &F2, Canara Bank Road,
Bommasandra Industrial Area Phase 1,
Bommasandra, Bangalore, 560 099, India

Unit II: Plot No 276-P & 277-P, Survey No-20,
Harohalli Industrial Area, Phase II,
Near Bannikuppe Village, Kanakapura
Taluk, Ramnagar District,
Harohalli, Karnataka 562112, India

NeoAnthem Lifesciences Private Limited

Unit III: 313-P,314-P, 318-P, Harohalli
Industrial Area, Phase II,
Kanakapura Taluk, Ramnagar District,
Harohalli, Karnataka, 562112, India

For further information please contact
investors.abl@anthembio.com or anthem@adfactorspr.com